Home > Companies > TTY Biopharm Company Limited

TTY Biopharm Company Limited

TTY Biopharm Co., Ltd. was established on July 22nd 1960. TTY is a Taiwan's leading pharmaceutical manufacturing company which specializes in the development of special formulations and new drugs. TTY focuses on research & development and innovation of antitumor and against severe infection's areas. We will continue to develop in healthcare product portfolio to support the physicians and patients with completed approach to disease treatment.

C-Suite On Deck

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Events

Medicinal Chemistry and Drug Design

World Drug Safety Congress Europe

Temperature Controlled Logistics And Security

80TH FIP WORLD CONGRESS OF PHARMACY AND PHARMACEUTICAL SCIENCES

7th Edition of Global Conference on Pharmaceutics and Novel Drug Delivery Systems

iPharma Expo 2022

Related News

BUSINESS INSIGHTS

GLOBAL PHARMACEUTICAL MARKET DRIVES INNOVATIVE DIGITALIZATION TO ACCELERATE DRUG DISCOVERY

Frost & Sullivan | June 17, 2022

Frost & Sullivan's recent analysis, Global Pharmaceuticals Outlook, finds that the accelerated drug development timelines are driving digitalization and innovation across the pharmaceutical value chain. Data, the decentralization of clinical trials, supply-chain resilience, digital therapeutics, and manufacturing automation are the key areas driving digitalization. The industry also ensures that healthcare will remain precise, preventive, and outcome-based in promoting social and financi...

PHARMA TECH

GANNEX RECEIVED U.S. FDA FAST TRACK DESIGNATION FOR ITS NASH DRUG CANDIDATE ASC42，AN FXR AGONIST

Gannex | December 14, 2020

Gannex, an entirely claimed organization of Ascletis Pharma Inc. (HKEX:1672) and completely committed to the R&D and commercialization of new medications in the field of NASH, reported today that it got Fast Track assignment from the U.S. Food and Drug Administration (FDA) for its non-alcoholic steatohepatitis (NASH) drug applicant ASC42. The U.S. FDA's Fast Track advancement program is intended to encourage the turn of events and speed up the survey of medications that ha...

PHARMACY MARKET

TAKEDA IS POISED TO COMMERCIALIZE NEXT GENERATION HUNTER'S DISEASE THERAPY THROUGH COLLABORATION WITH JCR PHARMACEUTICALS

Takeda Pharmaceutical Company Limited | October 01, 2021

Takeda Pharmaceutical Company Limited and JCR Pharmaceuticals Co., Ltd. today announce a geographically focused exclusive collaboration and license agreement to commercialize JR-141, a recombinant fusion protein under development of a next-generation antibody against the human transferrin receptor and the enzyme iduronate- 2-sulfatase (IDS), used to treat Hunter's disease (also called mucopolysaccharidosis type II or MPS II). Hunter's disease is caused by the lack of IDS and manifests it...

MOVILITAS.CLOUD™ VRS SOLUTION CLARIFIES DSCSA VERIFICATION FOR PHARMACEUTICAL WHOLESALE DISTRIBUTORS AND MANUFACTURERS

Movilitas | July 13, 2020

Movilitas announced today the availability of its Movilitas.Cloud™ Verification Router Service (VRS) solution that simplifies the verification process and compliance for pharmaceutical wholesale distributors and manufacturers. The new mobile app provides an out-of-the-box solution for the November 2020 Drug Supply Chain Security Act (DSCSA) saleable returns verification deadline. With the upcoming regulation, wholesale distributors must verify the serialized product identifi...